Development of a next generation allogeneic CAR-T cell platform without gene editing

Development of a next generation allogeneic CAR-T cell platform without gene editing

Modeling NKG2D-based CAR-T cell therapy in animals with acute myeloid leukemia

Modeling NKG2D-based CAR-T cell therapy in animals with acute myeloid leukemia

Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Celyad to Participate in Upcoming June 2019 Conferences

Celyad to Participate in Upcoming June 2019 Conferences

Celyad to Present Data at 24th Congress of the European Hematology Association

Celyad to Present Data at 24th Congress of the European Hematology Association

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces May 2019 Investor Conference Schedule

Celyad Announces May 2019 Investor Conference Schedule

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress

Celyad Announces April 2019 Investor Conference Schedule

Celyad Announces April 2019 Investor Conference Schedule

Conference call Celyad full year 2018

Conference call Celyad full year 2018

Celyad Reports Business Update and Full Year 2018 Financial and Operating Results

Celyad Reports Business Update and Full Year 2018 Financial and Operating Results

Celyad Appoints Filippo Petti as Chief Executive Officer

Celyad Appoints Filippo Petti as Chief Executive Officer